Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05884333

Cord Blood Transplant in Adults With Blood Cancers

Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults

Status
Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
54 (estimated)
Sponsor
Memorial Sloan Kettering Cancer Center · Academic / Other
Sex
All
Age
21 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Cord blood transplants (CBT) are a standard treatment for adults with blood cancers. MSK has developed a standard ("optimized") practice for cord blood transplant (CBT). This optimized practice includes how patients are evaluated for transplant, the conditioning treatment (standard chemotherapy and total body irradiation therapy) given to prepare the body for transplant, the amount of stem cells transplanted, and how patients are followed during and after transplant.The purpose of this study is to collect information about participant outcomes after CBT following MSK's optimized practice. The researchers will look at outcomes of the CBT treatment such as side effects, disease relapse, GVHD, and immune system recovery after CBT treatment.

Conditions

Interventions

TypeNameDescription
DRUGConditioning ChemotherapyConditioning: Cyclophosphamide (CY) 50 mg/kg x1 (day -6), Fludarabine (FLU) 30 mg/m2 x5 (days -6 to -2), Thiotepa (THIO) 5 mg/kg x2 (days -5 \& -4), Total Body Irradiation (TBI) 200 cGy x2 (days -2 \& -1). GVHD prophylaxis: Cyclosporine (CSA) 3 mg/kg q12 hours \& Mycophenolate Mofetil (MMF) 15 mg/kg q8 hours (starting IV day -3).
BIOLOGICALCord blood graftThe double-unit CB graft will be infused on day 0 per standard practice.

Timeline

Start date
2023-05-22
Primary completion
2028-05-22
Completion
2028-05-22
First posted
2023-06-01
Last updated
2025-09-08

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT05884333. Inclusion in this directory is not an endorsement.